Pulmonary arterial hypertension in pregnancy

Curr Opin Cardiol. 2023 May 1;38(3):250-256. doi: 10.1097/HCO.0000000000001034. Epub 2023 Mar 1.

Abstract

Purpose of review: Although pregnancy in pulmonary arterial hypertension (PAH) is considered high risk and contraindicated, the incidence is rising. It is paramount to understand the pathophysiology and effective management strategies to ensure optimal outcomes for maternal and fetal survival.

Recent findings: In this review, we highlight the outcomes of recent case series of PAH patients in pregnancy, with a focus on proper risk assessment and target goals of PAH therapy. These findings support the notion that the pillars of PAH management, including pulmonary vascular resistance reduction resulting in right heart functional improvement, and widening of the cardiopulmonary reserve, should serve as a blueprint for PAH management in pregnancy.

Summary: Multidisciplinary and tailored management of PAH in pregnancy, with emphasis on optimizing right heart function prior to delivery, can result in excellent clinical outcomes in a referral pulmonary hypertension center.

Publication types

  • Review

MeSH terms

  • Female
  • Heart
  • Humans
  • Hypertension, Pulmonary* / therapy
  • Pregnancy
  • Pulmonary Arterial Hypertension* / therapy
  • Risk Assessment